{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:15:44Z","timestamp":1774008944447,"version":"3.50.1"},"reference-count":64,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: Chronic inflammation of the urinary bladder is associated with the bladder pain syndrome. The treatment alternatives in humans are far from satisfactory and need further attention. Well-established preclinical models have shown that pro-inflammatory cytokines contribute to the progress of the inflammatory response behind pain and hyperalgesia. Previously presented results indicate that treatment with CernitinTM pollen extracts active pharmaceutical ingredients (APIs) (Cernitin GBX and Cernitin T60) significantly alleviated pain in cyclophosphamide-induced urinary bladder inflammation in a rodent model through downregulation of PGD2 and cyclooxygenase-2 (COX-2) mediators when compared to the vehicle alone. The objective was to extend the original study by exploring the correlation between the two APIs and cytokines expression and to identify a possible biomarker pattern.\nMaterial and method: The Olink\u00ae Target 48 Mouse Cytokine assay was conducted on the homogenised tissue extracts of the bladder wall with induced inflammation from a previous study to identify the potential impacts on protein biomarkers.\nResults: The test revealed that treatment with the APIs significantly downregulated the cytokines interleukin (IL)-1\u03b1, IL-2, IL-4, IL-6, and with trend to significance the biomarkers IL-12 \u03b1, \u03b2, CCL4 and fibroblast growth factor 21 when administered in combination (GBX+T60) or each component alone, compared to vehicle controls.\nConclusion: This study identified seven cytokines that were significantly or markedly reduced. The results suggest that CernitinTM APIs impact a series of key pro-inflammatory biomarkers demonstrating an ability to restrain inflammation. Therefore, they warrant further investigation as potential therapeutic candidates<\/jats:p>","DOI":"10.2340\/sju.v61.45606","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:12:57Z","timestamp":1774001577000},"page":"58-63","source":"Crossref","is-referenced-by-count":0,"title":["Treatment with CernitinTM of induced urinary bladder inflammation downregulates relevant pro-inflammatory biomarkers \u2013 an experimental in vivo rodent model"],"prefix":"10.2340","volume":"61","author":[{"given":"Nishtman","family":"Dizeyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Aug\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lluel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Grabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"145745","doi-asserted-by":"crossref","unstructured":"Jhang JF, Kuo HC. Pathomechanism of interstitial cystitis\/bladder pain syndrome and mapping the heterogeneity of disease. Int Neurourol J. 2016;20:95\u2013104.","DOI":"10.5213\/inj.1632712.356"},{"key":"145746","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5213\/inj.1632712.356","DOI":"10.5213\/inj.1632712.356"},{"key":"145747","doi-asserted-by":"crossref","unstructured":"Neuhaus J, Berndt-Paetz M, Gonsior A. Biomarkers in the light of the etiopathology of IC\/BPS. Diagnostics. 2021;11(12):2231.","DOI":"10.3390\/diagnostics11122231"},{"key":"145748","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/diagnostics11122231","DOI":"10.3390\/diagnostics11122231"},{"key":"145749","doi-asserted-by":"crossref","unstructured":"Quentin Clemens J, Erickson DR, Varela NP, et al. Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome. J Urol. 2022;208(1):34\u201342.","DOI":"10.1097\/JU.0000000000002756"},{"key":"145750","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/JU.0000000000002756","DOI":"10.1097\/JU.0000000000002756"},{"key":"145751","doi-asserted-by":"crossref","unstructured":"Aug\u00e9 C, Gam\u00e9 X, Vergnolle N, et al. Characterization and validation of a chronic model of cyclophosphamide-induced interstitial cystitis\/bladder pain syndrome in rats. Front Pharmacol. 2020;11:1305.","DOI":"10.3389\/fphar.2020.01305"},{"key":"145752","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2020.01305","DOI":"10.3389\/fphar.2020.01305"},{"key":"145753","doi-asserted-by":"crossref","unstructured":"Zheng Z, Zhang J, Zhang C, et al. The study on the function and cell source of interleukin-6 in interstitial cystitis\/bladder painful syndrome rat model. Immun Inflamm Dis. 2021;9(4):1520\u20131528.","DOI":"10.1002\/iid3.505"},{"key":"145754","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/iid3.505","DOI":"10.1002\/iid3.505"},{"key":"145755","doi-asserted-by":"crossref","unstructured":"Aug\u00e9 C, Dizeyi N, Ramnemark L, et al. Experimental in vivo model to evaluate the impact of CernitinTM on pain response on induced chronic bladder inflammation. Scand J Urol. 2022;56(4):320\u2013328.","DOI":"10.1080\/21681805.2022.2090602"},{"key":"145756","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2090602","DOI":"10.1080\/21681805.2022.2090602"},{"key":"145757","doi-asserted-by":"crossref","unstructured":"Tay C, Grundy L. Animal models of interstitial cystitis\/bladder pain syndrome. Front Physiol. 2023;14:1232017.","DOI":"10.3389\/fphys.2023.1232017"},{"key":"145758","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphys.2023.1232017","DOI":"10.3389\/fphys.2023.1232017"},{"key":"145759","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544\u2013551.","DOI":"10.1016\/j.eururo.2009.05.046"},{"key":"145760","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2009.05.046","DOI":"10.1016\/j.eururo.2009.05.046"},{"key":"145761","doi-asserted-by":"crossref","unstructured":"Chabot S, Dizeyi N, Ramnemark L, et al. Impact of CernitinTM on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms. Phytomedicine Plus. 2021;1:100057.","DOI":"10.1016\/j.phyplu.2021.100057"},{"key":"145762","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.phyplu.2021.100057","DOI":"10.1016\/j.phyplu.2021.100057"},{"key":"145763","doi-asserted-by":"crossref","unstructured":"Turner MD, Nedjai B, Hurst T, et al. Cytokines and chemokines: at the crossroads of cell signaling and inflammatory disease. Biochim Biophys Acta. 2014;1843(11):2563\u20132582.","DOI":"10.1016\/j.bbamcr.2014.05.014"},{"key":"145764","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.bbamcr.2014.05.014","DOI":"10.1016\/j.bbamcr.2014.05.014"},{"key":"145765","doi-asserted-by":"crossref","unstructured":"Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27\u201337.","DOI":"10.1097\/AIA.0b013e318034194e"},{"key":"145766","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/AIA.0b013e318034194e","DOI":"10.1097\/AIA.0b013e318034194e"},{"key":"145767","doi-asserted-by":"crossref","unstructured":"Yu WR, Jiang YH, Jhang JF, et al. Use of urinary cytokine and chemokine levels for identifying bladder conditions and predicting treatment outcomes in patients with interstitial cystitis\/bladder pain syndrome. Biomedicines. 2022;10(5):1149.","DOI":"10.3390\/biomedicines10051149"},{"key":"145768","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/biomedicines10051149","DOI":"10.3390\/biomedicines10051149"},{"key":"145769","doi-asserted-by":"crossref","unstructured":"Abbas AK. The surprising story of IL-2: from experimental models to clinical application. Am J Pathol. 2020;190(9):1776\u20131781.","DOI":"10.1016\/j.ajpath.2020.05.007"},{"key":"145770","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ajpath.2020.05.007","DOI":"10.1016\/j.ajpath.2020.05.007"},{"key":"145771","doi-asserted-by":"crossref","unstructured":"Torres T, Mendes-Bastos P, Cruz MJ, et al. Interleukin-4 and atopic dermatitis: why does it matter? A narrative review. Dermatol Ther. 2025;15(3):579\u2013597.","DOI":"10.1007\/s13555-025-01352-y"},{"key":"145772","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-025-01352-y","DOI":"10.1007\/s13555-025-01352-y"},{"key":"145773","unstructured":"Ullrich KA-M, Schulze LL, Paap E-M, et al. Immunology of IL-12: an update on functional activities and implications for disease. EXCLI J. 2020;19:1563\u20131589."},{"key":"145774","unstructured":"https:\/\/doi.org\/10.17179\/excli2020-3104"},{"key":"145775","doi-asserted-by":"crossref","unstructured":"Chang TT, Yang HY, Chen C, et al. CCL4 inhibition in atherosclerosis: effects of plaque stability, endothelial cell adhesiveness, and macrophages activation. Int J Mol Sci. 2020;21(18):6567.","DOI":"10.3390\/ijms21186567"},{"key":"145776","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms21186567","DOI":"10.3390\/ijms21186567"},{"key":"145777","doi-asserted-by":"crossref","unstructured":"Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol. 2023;14:121220426.","DOI":"10.3389\/fendo.2023.1220426"},{"key":"145778","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fendo.2023.1220426","DOI":"10.3389\/fendo.2023.1220426"},{"key":"145779","doi-asserted-by":"crossref","unstructured":"Kureshi CT, Dougan SK. Cytokines in cancer. Cancer Cell. 2025;43(1):15\u201335.","DOI":"10.1016\/j.ccell.2024.11.011"},{"key":"145780","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ccell.2024.11.011","DOI":"10.1016\/j.ccell.2024.11.011"},{"key":"145781","doi-asserted-by":"crossref","unstructured":"Wullt B, Butler DSC, Ambite I, et al. Immunomodulation \u2013 a molecular solution to treating patients with severe bladder pain syndrome? Eur Urol Open Sci. 2021:31:49\u201358.","DOI":"10.1016\/j.euros.2021.07.003"},{"key":"145782","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euros.2021.07.003","DOI":"10.1016\/j.euros.2021.07.003"},{"key":"145783","doi-asserted-by":"crossref","unstructured":"Smaldone MC, Vodovotz Y, Tyagi Y, et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology. 2009;73(2):421\u2013426.","DOI":"10.1016\/j.urology.2008.07.031"},{"key":"145784","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.urology.2008.07.031","DOI":"10.1016\/j.urology.2008.07.031"},{"key":"145785","doi-asserted-by":"crossref","unstructured":"Jiang YH, Jhang JF, Hsu YH, et al. Usefulness of urinary biomarkers for assessing bladder condition and histopathology in patients with interstitial cystitis\/bladder pain syndrome. Int J Mol Sci. 2022;23(19):12044.","DOI":"10.3390\/ijms231912044"},{"key":"145786","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms231912044","DOI":"10.3390\/ijms231912044"},{"key":"145787","doi-asserted-by":"crossref","unstructured":"Dinarello CA, Simon A, Van Der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11(8):633\u2013652.","DOI":"10.1038\/nrd3800"},{"key":"145788","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrd3800","DOI":"10.1038\/nrd3800"},{"key":"145789","doi-asserted-by":"crossref","unstructured":"Dizeyi N, Mattisson IY, Ramnemark L, et al. The effects of Cernitin\u00ae on inflammatory parameters and benign prostatic hyperplasia: an in vitro study. Phytother Res. 2019;33(9):2457\u20132464.","DOI":"10.1002\/ptr.6438"},{"key":"145790","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ptr.6438","DOI":"10.1002\/ptr.6438"},{"key":"145791","doi-asserted-by":"crossref","unstructured":"Sant GR, Kempuraj D, Marchand JE, et al. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007;69(4 Suppl):34\u201340.","DOI":"10.1016\/j.urology.2006.08.1109"},{"key":"145792","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.urology.2006.08.1109","DOI":"10.1016\/j.urology.2006.08.1109"},{"key":"145793","doi-asserted-by":"crossref","unstructured":"Sugaya K, Nishijima S, Yamada T, et al. Molecular analysis of adrenergic receptor genes and interleukin-4\/interleukin-4 receptor genes in patients with interstitial cystitis. J Urol. 2002;168(6):2668\u20132671.","DOI":"10.1016\/S0022-5347(05)64241-3"},{"key":"145794","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0022-5347(05)64241-3","DOI":"10.1016\/S0022-5347(05)64241-3"},{"key":"145795","doi-asserted-by":"crossref","unstructured":"Tait Wojno ED, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: room for discovery. Immunity. 2019;50(4):851\u2013870.","DOI":"10.1016\/j.immuni.2019.03.011"},{"key":"145796","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.immuni.2019.03.011","DOI":"10.1016\/j.immuni.2019.03.011"},{"key":"145797","doi-asserted-by":"crossref","unstructured":"Lemmon B, Kyrgiou M, Mullins E, et al. Cytokines in bladder pain syndrome: a review of the literature. Int Urogynecol J. 2024;35(6):1119\u20131129.","DOI":"10.1007\/s00192-024-05778-4"},{"key":"145798","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00192-024-05778-4","DOI":"10.1007\/s00192-024-05778-4"},{"key":"145799","unstructured":"Zmigrodzka M, Rzepecka A, Krzyzowska M, et al. The cyclooxygenase-2\/prostaglandin E 2 pathway and its role in the pathogenesis of human and dog hematological malignancies. J Physiol Pharmacol. 2018;69(5):653\u2013661."},{"key":"145800","unstructured":"https:\/\/doi.org\/10.26402\/jpp.2018.5.01"},{"key":"145801","doi-asserted-by":"crossref","unstructured":"Wang C, Li GW, Huang LY. Prostaglandin E2 potentiation of P2X3 receptor mediated currents in dorsal root ganglion neurons. Mol Pain. 2007;32:22.","DOI":"10.1186\/1744-8069-3-22"},{"key":"145802","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1744-8069-3-22","DOI":"10.1186\/1744-8069-3-22"},{"key":"145803","doi-asserted-by":"crossref","unstructured":"De Brito TV, Dias Junior GJ, da Cruz Junior JS, et al. Gabapentin attenuates intestinal inflammation: role of PPAR-gamma receptor. Eur J Pharmacol. 2020;873:172974.","DOI":"10.1016\/j.ejphar.2020.172974"},{"key":"145804","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.172974","DOI":"10.1016\/j.ejphar.2020.172974"},{"key":"145805","doi-asserted-by":"crossref","unstructured":"Aug\u00e9 C, Chene G, Dubourdeau M, et al. Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder. Eur J Pharmacol. 2013;707:32\u201340.","DOI":"10.1016\/j.ejphar.2013.03.008"},{"key":"145806","unstructured":"https:\/\/doi.org\/10.1016\/j.ejphar2013.03.008"},{"key":"145807","doi-asserted-by":"crossref","unstructured":"Akdere H, Blir B, Kuvan HC, et al. Interleukins in urological diseases. Discov Med. 2025;37:647\u2013658.","DOI":"10.24976\/Discov.Med.202537195.56"},{"key":"145808","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.24976\/Discov.Med.202537195.56","DOI":"10.24976\/Discov.Med.202537195.56"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45606\/53233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45606\/53233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:13:17Z","timestamp":1774001597000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/45606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":64,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.45606","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}